Losmapimod, a p38 MAPK inhibitor, is a promising drug developed by Fulcrum Therapeutics that is the first compound to target the underlying mechanism of FSHD by inhibiting DUX4. Phase 2 data for ...

This insight into the DUX4 regulatory pathway led the team to review existing p38/ MAPK inhibitors and identify losmapimod as a compound with the potential to address the root cause of FSHD by ...

Levitchi Benea and colleagues wanted to assess the safety and tolerability of losmapimod (Fulcrum Therapeutics), a small molecule p38 alpha/beta MAPK inhibitor, in facioscapulohumeral muscular ...

Losmapimod is a selective p38α/β mitogen activated protein kinase (MAPK) inhibitor. Fulcrum exclusively in-licensed losmapimod from GSK following Fulcrum’s discovery of the role of p38α/β ...

About LosmapimodLosmapimod is an investigational, selective p38α/β mitogen activated protein kinase (MAPK) inhibitor. Fulcrum exclusively in-licensed losmapimod from GSK following Fulcrum’s ...

Treatment with losmapimod and placebo had similar results with respect to primary, secondary endpoints. No treatment-related severe adverse events, discontinuation or deaths were recorded with ...

Following the live webcast, an archived replay will also be available. Losmapimod is a selective p38a/ß mitogen activated protein kinase (MAPK) inhibitor. Fulcrum exclusively in-licensed losmapimod ...